CSL Australia

Activities: Research & Development Pharmaceutical

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Media

GlobalData publishes analysis of top 25 global pharma companies

The data and analytics company has tracked the market cap performance of the top 25 pharma companies for the quarter ending 31 March, 2018 compared to 2017 revealing a number of interesting insights
Media

GlobalData names top 25 global pharma companies by market cap

The performance highlights of the top 25 publicly traded global pharma companies for the year 2017 have been confirmed in the latest research from GlobalData
Design & Build

Seqirus to build £22m vaccine production facility in Liverpool

The investment includes a manufacturing facility and a new warehouse
Finance

Novartis to sell influenza vaccines business to CSL for US$275m

Non-influenza business of Novartis Vaccines is being bought by GlaxoSmithKline, as announced in April
Subscribe now